The study will enroll recurrent aseptic pleural effusion patients who are designated by their physician as needing treatment to control the fluid. Baseline assessment will include a history and physical, chest imaging and quality of life questionnaires. After ACES implantation, patients will remain under hospital care for general observation as per standard-of-care before being discharged home with access to electronic diaries for tracking pain and dyspnea.
Pleural Dynamics is the first company to provide a fully implantable automatic effusion shunt that is powered by normal breathing and is designed for continuous symptom relief, and does not require an extended hospital stay, a catheter external to the chest, or expensive drainage canisters." The current standard of care, pleurodesis, is often painful, requires an extended hospital stay, and is often unsuccessful requiring additional procedures to manage the effusion1. While an alternate approach-indwelling pleural catheters-exists, it requires that the patient have a portion of the catheter to be external to the chest and requires frequent drainage into proprietary external canisters to relieve symptoms. Pleural Dynamics' patented ACES™ System addresses these shortcomings with its' one-piece, fully implanted system that can be placed during a short hospital stay. This technology is designed to use normal breathing motion to automatically pump pleural effusion fluid out of the chest to the abdomen for reabsorption by the body eliminating the need for an external catheter and frequent drainage, providing ongoing symptom relief.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
25
The catheter pump chamber is placed with part of the chamber between adjacent ribs and part of the chamber under the skin and external to the ribs. The pump chamber is used to transfer pleural fluid into the peritoneal cavity.
Memorial Healthcare System
Hollywood, Florida, United States
Johns Hopkins School of Medicine
Baltimore, Maryland, United States
University of North Carolina Pulmonary and Critical Care Medicine
Chapel Hill, North Carolina, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Primary Efficacy Endpoint
Percentage change in pleural effusion volume via chest CT from baseline
Time frame: 30 days
Adverse Events
Rate of Adverse Events (serious and non-serious) including hospitalizations/visits
Time frame: 30 and 60 days
Pleurodesis
Rate of Pleurodesis
Time frame: 30 and 60 days
VAS Breathlessness Score
Change in VAS Breathlessness Score
Time frame: 30 and 60 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.